Physician profile
Nicole E Rich
NPI 1033408182
$18,630.90
in general payments reported to CMS, 2019-2025
11 companies · $4,743 in 2025
The $4,743 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $50.82 · 2022: $6,176 · 2023: $5,086 · 2024: $2,125 · 2025: $4,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,907 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,770 · Food and Beverage: $1,134 · Travel and Lodging: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,907.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,770.00 |
| Food and Beverage | $1,134.37 |
| Travel and Lodging | $142.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,743.36 | 2022-2025 | Imfinzi |
| Madrigal Pharmaceuticals | $4,657.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Exelixis INC. | $1,854.45 | 2019-2023 | Cabometyx |
| Genentech USA, INC. | $1,624.76 | 2024 | Tecentriq |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $416.67 | 2019 | |
| Shockwave Medical, INC | $162.43 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $94.26 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.58 | 2024 | Xifaxan |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.